

PHARMACY PRIOR AUTHORIZATION REQUEST FORM
KYMRIAH®

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:	HCPCS Code:	

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Kymriah™ (tisagenlecleucel)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
1. Is the requesting provider in the Kymriah® REMS program?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does the member have an active infection, including hepatitis B, hepatitis C, human immunodeficiency virus (HIV), and influenza?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Does the member have an inflammatory disorder?	<input type="checkbox"/>	<input type="checkbox"/>	
4. Does the member have adequate and stable liver, kidney, and cardiac function?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. If the member is a sexually active female of reproductive age, a negative pregnancy test must be documented	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
6. Does the member have any of the following: <ul style="list-style-type: none"> • Isolated extra-medullary disease • Concomitant genetic syndrome associated with BM failure states • Burkitt's lymphoma/leukemia • Grade 2 to 4 graft versus host disease • CNS prophylaxis treatment • History of primary CNS lymphoma or active CNS involvement by malignancy • Worsening of leukemia burden following lymphodepleting chemotherapy 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

ACUTE LYMPHOBLASTIC LEUKEMIA			
1. Is the request for treatment of acute lymphoblastic leukemia?	<input type="checkbox"/>	<input type="checkbox"/>	Please Provide Documentation
2. Is the member between the ages of 3-25 years?	<input type="checkbox"/>	<input type="checkbox"/>	Please Provide Documentation
3. Are B cells CD 19 positive as confirmed by testing or analysis?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Does the member have relapsed or refractory disease?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. Does the member have a Karnofsky score or Lansky score > 50?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
B- CELL LYMPHOMA			
1. Is the request for treatment of B-cell lymphoma?	<input type="checkbox"/>	<input type="checkbox"/>	Please Provide Documentation
2. Is the member at least 18 years of age?	<input type="checkbox"/>	<input type="checkbox"/>	Please Provide Documentation
3. Does the member have CD-19 positive disease?	<input type="checkbox"/>	<input type="checkbox"/>	Please Provide Documentation
4. Does the member have primary central nervous system lymphoma?	<input type="checkbox"/>	<input type="checkbox"/>	Please Provide Documentation
5. Does the member have an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1?	<input type="checkbox"/>	<input type="checkbox"/>	Please Provide Documentation
6. Has the member been unresponsive or refractory to at least 2 lines of systemic therapy, which must include anti CD-20 therapy and an anthracycline containing regimen?	<input type="checkbox"/>	<input type="checkbox"/>	Please Provide Documentation
7. Does the member have disease progression or relapse post-autologous stem cell transplant?	<input type="checkbox"/>	<input type="checkbox"/>	Please Provide Documentation
8. Does the member have any of the following: <ul style="list-style-type: none"> • Isolated extra-medullary disease • Concomitant genetic syndrome associated with BM failure states • Burkitt's lymphoma/leukemia • Grade 2 to 4 graft versus host disease • CNS prophylaxis treatment • History of primary CNS lymphoma or active CNS involvement by malignancy • Worsening of leukemia burden following lymphodepleting chemotherapy 	<input type="checkbox"/>	<input type="checkbox"/>	Please Provide Documentation
REFRACTORY FOLLICULAR LYMPHOMA			
1. Does documentation show a diagnosis of relapsing or refractory follicular lymphoma grade 1, 2, or 3A?	<input type="checkbox"/>	<input type="checkbox"/>	Please Provide Documentation
2. Is the member at least 18 years of age?	<input type="checkbox"/>	<input type="checkbox"/>	Please Provide Documentation
3. Does the member have an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1?	<input type="checkbox"/>	<input type="checkbox"/>	Please Provide Documentation
4. Does clinical documentation show ONE of the following criteria: <ul style="list-style-type: none"> • No response or refractory to at least 2 lines of systemic therapy, which must include the following: <ul style="list-style-type: none"> ○ Anti-CD20 therapy ○ An alkylating containing regimen • Disease progression or relapsed during or within 6 months of anti-CD20 maintenance therapy following at least 2 lines of systemic therapy • Disease progression or relapse post-autologous stem cell transplant (ASCT) 	<input type="checkbox"/>	<input type="checkbox"/>	Please Provide Documentation

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.

Additional information:

Physician's Signature:

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy PHARM-M003
Origination Date: 04/13/2018
Reviewed/Revised Date: 10/26/2022
Next Review Date: 10/26/2023
Current Effective Date: 11/01/2022

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.